Siemens ponders future of dental business
This article was originally published in Clinica
German multinational Siemens is taking another step in the ongoing restructuring of its medical engineering division. The company is evaluating ways of improving worldwide market coverage of its dental equipment business, but stresses it is under no time pressure. This could take the shape of an outright sale or a collaboration with a partner. An outright sale would be the company's second withdrawal from a medtech area after selling its pacemaker business two years ago.
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.